Obesity remains one of the most pressing public health challenges across Europe, affecting millions and straining healthcare systems. With injectable treatments like semaglutide and tirzepatide revolutionizing weight management, a major hurdle persists: the majority of patients regain significant weight within a year of stopping these therapies. Recent research unveiled at the European Congress on Obesity in Istanbul offers hope through a simple daily pill called orforglipron, an oral glucagon-like peptide-1 receptor agonist (GLP-1 RA), which demonstrates remarkable ability to sustain weight loss post-injection.

This breakthrough, detailed in a phase 3b clinical trial known as ATTAIN-MAINTAIN and published in Nature Medicine, involved participants who had achieved substantial weight reduction on injectables. Transitioning to orforglipron allowed them to preserve 75% to 85% of their lost weight over 52 weeks, compared to just 38% to 50% on placebo. Such findings could transform long-term obesity care, making maintenance more accessible and less invasive.

The Challenge of Weight Regain in Obesity Treatment

Glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, mimic the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and improve insulin sensitivity. Injectable versions such as semaglutide (marketed as Wegovy or Ozempic) and tirzepatide (Zepbound or Mounjaro, a dual GLP-1/GIP agonist) have enabled average weight losses of 15-20% in clinical trials. However, real-world data reveals that up to two-thirds of this loss rebounds upon discontinuation, often due to physiological adaptations like slowed metabolism and heightened hunger signals.

In Europe, where obesity prevalence hovers around 23% for adults—highest in countries like Malta (29%) and the UK (28%)—this regain exacerbates risks for type 2 diabetes, cardiovascular disease, and certain cancers. The World Obesity Federation projects that by 2030, over 300 million Europeans could live with severe obesity without intervention. Ongoing pharmacological support is thus essential, but injections pose barriers: needle phobia, cost, and inconvenience deter adherence.

Inside the ATTAIN-MAINTAIN Trial

Conducted across 29 US sites, the ATTAIN-MAINTAIN trial built on the SURMOUNT-5 study, where tirzepatide outperformed semaglutide for weight loss. Of 376 participants (aged ~48, mostly female, average starting weight 90-94 kg post-loss), half switched directly from injections to once-daily orforglipron (titrated from 12mg to a maximum tolerated dose up to 36mg) or placebo for one year. All received lifestyle counseling emphasizing diet and exercise.

Two cohorts were analyzed: one from tirzepatide users (205 participants) and one from semaglutide (171). Inclusion required at least 5% weight loss and a plateau (less than 5% change in final 12 weeks of injections). The primary endpoint measured percentage of prior weight loss maintained, using both modified treatment-regimen (handling deviations) and efficacy estimands.

This design mirrors real-world scenarios, addressing the 'maintenance phase' gap in obesity management.

Impressive Results on Weight Preservation

In the tirzepatide cohort, orforglipron users retained 74.7% of their weight loss versus 49.2% on placebo—a statistically significant difference (P<0.001). For semaglutide switchers, retention reached 79.3% versus 37.6%. Overall, mean body weight changes from trial start were minimal: -3.9% further loss in tirzepatide group on drug, versus regain on placebo.

• 43-55% on orforglipron maintained ≥80% loss, vs. 7-16% on placebo.
• Waist circumference reductions held: ~9-11 cm sustained.
• Cardiometabolic gains persisted: improved HbA1c, lipids, blood pressure.

These outcomes position orforglipron as a viable bridge, potentially seven times more effective than placebo at preventing substantial regain.

Safety Profile and Tolerability

Orforglipron's side effects mirrored injectables: gastrointestinal issues like nausea (10-15% early on), constipation, and diarrhea, mostly mild and transient. Discontinuation rates were low (5-7%), comparable to placebo. No new safety signals emerged—no severe pancreatitis or thyroid issues. Liver enzyme elevations were rare and resolved.

Direct switch from high-dose injectables was well-tolerated, suggesting practicality for clinical use. Long-term data beyond one year is needed, but initial tolerability supports broader adoption.

Photo by Clay Banks on Unsplash

Expert Perspectives from European Researchers

Lead investigators include Prof. Carel le Roux from University College Dublin and Ulster University, highlighting European involvement. Dr. Marie Spreckley of the University of Cambridge noted, "Swallowing a pill might be more attractive... obesity is a chronic, relapsing disease requiring ongoing treatment." Dr. Simon Cork from Anglia Ruskin University called it "really important," praising sustained cardiometabolic benefits.

At ECO 2026 in Istanbul, discussions emphasized scalability: oral agents could democratize access in resource-limited European regions.

Obesity Landscape in Europe

Europe faces a burgeoning crisis: WHO data shows adult obesity tripling since 1980s, with projections of 268 million cases by 2030. Southern and Eastern nations lead: Malta 28.7%, Russia 30.3%. Costs exceed €200 billion annually in healthcare and productivity losses. GLP-1 uptake is rising—UK NHS trials Ozempic-like drugs—but supply shortages and regain undermine impact.

WHO European Region obesity trends underscore urgency for maintenance strategies.

Regulatory Pathway and Availability in Europe

Orforglipron (branded Foundayo in US, FDA-approved April 2026) has EMA pediatric investigation plan; full submission expected mid-2026. UK MHRA review anticipated soon after. Rival oral semaglutide (Rybelsus) exists for diabetes; obesity approvals pending. Cost advantages (pills cheaper to produce) could enhance NHS access.

European Congress on Obesity site for ongoing updates.

Integrating Orforglipron with Lifestyle Changes

Trials combined drug with counseling: 500-600 kcal deficit diets, 150+ minutes weekly exercise. Step counts of 8,500 daily correlated with sustained loss. Behavioral therapy addresses psychological factors like emotional eating.

• Mediterranean diet: Emphasizes whole foods, proven in European cohorts.
• Resistance training: Preserves muscle mass lost on GLP-1s.
• Mindful eating apps: Track progress without obsession.

Holistic approaches amplify pill efficacy.

Future Directions and Challenges

Ongoing trials explore combinations (e.g., with GIP/amylin agonists) and head-to-head vs. injectables. Pediatric/adolescent studies loom amid rising youth obesity. Challenges: access equity, long-term adherence, resistance development. European universities like Cambridge and Dublin lead pharmacogenomics to personalize dosing.

ATTAIN-MAINTAIN full paper in Nature Medicine.

Photo by Dorian Labbe on Unsplash

Implications for European Healthcare

For Europe's 200+ million overweight adults, orforglipron promises cost-effective, patient-friendly maintenance. Integrated care models—GP prescribing, dietitian support—could stem epidemic tide. Research hubs in Ireland, UK, Germany drive innovation, positioning continent as GLP-1 leader.

As Prof. le Roux states, this shifts paradigm: from short-term loss to lifelong management.